Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Kenyon

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Regulatory Toxicology and Pharmacology : RTP|December 12, 2012
Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesisPatricia Ellis, Michelle Kenyon, Krista Dobo
The Lancet. Haematology|May 14, 2021
Global collaboration led by the EBMT Nurses GroupEugenia Trigoso, Julia Ruiz, Michelle Kenyon, et al.
Regulatory Toxicology and Pharmacology : RTP|May 18, 2024
Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicantsCatrin Hasselgren, Michelle Kenyon, Lennart T Anger, et al.
Blood|January 2, 2003
Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200Aloysius Y L Ho, Michelle Kenyon, Ihab El-Hemaidi, et al.
Science Advances|May 27, 2026
Complex versus simple <i>N</i>-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigmsXiaowen Sun, Maik Schuler, Shaofei Zhang, et al.
Blood|April 3, 2004
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningAloysius Y L Ho, Antonio Pagliuca, Michelle Kenyon, et al.
Bone Marrow Transplantation|October 21, 2020
Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 yearsFiona L Dignan, Angela Hamblin, Amelia Chong, et al.
Clinical Hematology International|September 21, 2022
The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common ToxicitiesRose Ellard, Michelle Kenyon, Daphna Hutt, et al.
Internal Medicine Journal|April 7, 2018
Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantationAditya Tedjaseputra, Donal McLornan, Jill McCormick, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Regulatory Toxicology and Pharmacology : RTP|December 12, 2012
Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesisPatricia Ellis, Michelle Kenyon, Krista Dobo
The Lancet. Haematology|May 14, 2021
Global collaboration led by the EBMT Nurses GroupEugenia Trigoso, Julia Ruiz, Michelle Kenyon, et al.
Regulatory Toxicology and Pharmacology : RTP|May 18, 2024
Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicantsCatrin Hasselgren, Michelle Kenyon, Lennart T Anger, et al.
Blood|January 2, 2003
Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200Aloysius Y L Ho, Michelle Kenyon, Ihab El-Hemaidi, et al.
Science Advances|May 27, 2026
Complex versus simple <i>N</i>-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigmsXiaowen Sun, Maik Schuler, Shaofei Zhang, et al.
Blood|April 3, 2004
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningAloysius Y L Ho, Antonio Pagliuca, Michelle Kenyon, et al.
Bone Marrow Transplantation|October 21, 2020
Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 yearsFiona L Dignan, Angela Hamblin, Amelia Chong, et al.
Clinical Hematology International|September 21, 2022
The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common ToxicitiesRose Ellard, Michelle Kenyon, Daphna Hutt, et al.
Internal Medicine Journal|April 7, 2018
Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantationAditya Tedjaseputra, Donal McLornan, Jill McCormick, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Pageof 5